.jpg)
Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
Bayer and Suzhou Puhe BioPharma Co., Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma's oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor.
Bayer and Suzhou Puhe BioPharma Co., Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma's oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor.
